

Tata India Pharma & Healthcare Fund

(An open ended equity scheme investing in Pharma and Healthcare Services Sector)



As on 31st August 2021

INVESTMENT STYLE

Primarily focuses on investment in at least 80% of its net assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India.

INVESTMENT OBJECTIVE

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.

DATE OF ALLOTMENT

December 28, 2015

FUND MANAGER

Meeta Shetty (Managing Since 09-Mar-21 and overall experience of 15 years)

BENCHMARK

Nifty Pharma TRI
Benchmark Risk-O-Meter - Very High

NAV

Direct - IDCW	:	20.0277
Direct - Growth	:	20.0277
Regular - IDCW	:	18.2462
Regular - Growth	:	18.2462

FUND SIZE

Rs. 609.91 (Rs. in Cr.)

MONTHLY AVERAGE AUM

Rs. 596.66 (Rs. in Cr.)

TURN OVER

Portfolio Turnover (Total)	42.21%
Portfolio Turnover (Equity component only)	42.21%

EXPENSE RATIO**

Direct	1.05
Regular	2.69

**Note: The rates specified are actual month end expenses charged as on Aug 31, 2021. The above ratio includes the Service tax on Investment Management Fees. The above ratio excludes, borrowing cost, wherever applicable.

VOLATILITY MEASURES ^ FUND BENCHMARK

Std. Dev (Annualised)	18.41	24.42
Sharpe Ratio	0.30	0.13
Portfolio Beta	0.70	1.00
R Squared	0.86	1.00
Treynor	2.30	0.90
Jenson	0.98	NA

^ Risk-free rate based on the FBIL Overnight MIBOR rate of 3.38% as on Aug 31, 2021

For calculation methodology please refer to Pg 70

MINIMUM INVESTMENT / MULTIPLES FOR NEW INVESTMENT

Rs. 5,000/- and in multiples of Re. 1/- thereafter.

ADDITIONAL INVESTMENT / MULTIPLES FOR EXISTING INVESTORS

Rs. 1,000/- and in multiples of Re. 1/- thereafter.

LOAD STRUCTURE

Entry Load : Not Applicable

Exit Load : 0.25% of NAV if redeemed/switched out before 30 days from the date of allotment.

Please refer to our Tata Mutual Fund website for fundamental changes, wherever applicable



PORTFOLIO

Company name	No. of Shares	Market Value Rs. Lakhs	% of Assets
Equity & Equity Related Total		59831.80	98.11
Healthcare Services			
Apollo Hospitals Enterprise Ltd.	78000	3876.25	6.36
Narayana Hrudayalaya Ltd.	491420	2656.37	4.36
Fortis Healthcare Ltd.	795000	2309.48	3.79
Krishna Institute Of Medical Sciences Ltd.	116982	1503.69	2.47
Syngene International Ltd.	200000	1282.70	2.10
Metropolis Healthcare Ltd.	43000	1214.13	1.99
Healthcare Global Enterprises Ltd.	410000	981.95	1.61
Pharmaceuticals			
Sun Pharmaceutical Industries Ltd.	867100	6885.21	11.29
Divi Laboratories Ltd.	104500	5406.41	8.86
Dr Reddys Laboratories Ltd.	103500	4868.69	7.98
Cipla Ltd.	500000	4739.00	7.77
Alkem Laboratories Ltd.	111365	4319.40	7.08
Ipca Laboratories Ltd.	133726	3443.85	5.65
J.B.Chemicals & Pharmaceuticals Ltd.	103000	1753.73	2.88
Procter & Gamble Health Ltd.	26000	1414.24	2.32
Aurobindo Pharma Ltd.	190000	1381.87	2.27
Indoco Remedies Ltd.	279000	1338.50	2.19
Fdc Ltd.	378183	1307.19	2.14
Ajanta Pharma Ltd.	53087	1182.67	1.94
Lupin Ltd.	123000	1178.16	1.93
Sanofi India Ltd.	13000	1171.79	1.92

Company name	No. of Shares	Market Value Rs. Lakhs	% of Assets
Gland Pharma Ltd.	25662	999.25	1.64
Abbott India Ltd.	5100	982.88	1.61
Glenmark Pharmaceuticals Ltd.	167000	885.60	1.45
Glaxosmithkline Pharmaceuticals Ltd.	53363	815.23	1.34
Other Equities ^		1933.56	3.17
Repo		1456.50	2.39
Portfolio Total		61288.30	100.49
Net Current Liabilities		-297.22	-0.49
Net Assets		60991.08	100.00

^ Exposure less than 1% has been clubbed under Other Equities

SIP - If you had invested INR 10000 every month

	1 Year	3 Year	5 Year	7 Year	10 Year	Since Inception
Total Amount Invested (Rs.)	120,000	360,000	600,000	NA	NA	680,000
Total Value as on Aug 31, 2021 (Rs.)	146,666	615,698	1,113,550	NA	NA	1,264,564
Returns	43.63%	38.16%	25.00%	NA	NA	21.87%
Total Value of B: Nifty Pharma TRI	137,244	539,431	905,110	NA	NA	1,009,685
B: Nifty Pharma TRI	27.69%	28.11%	16.46%	NA	NA	13.85%
Total Value of AB: Nifty 50 TRI	150,620	535,666	983,591	NA	NA	1,169,494
AB: Nifty 50 TRI	50.48%	27.59%	19.86%	NA	NA	19.07%

(Inception date :28-Dec-2015) (First Installment date : 01-Jan-2016)

Past performance may or may not be sustained in the future. Returns greater than 1 year period are compounded annualized. Income Distribution cum capital withdrawals are assumed to be reinvested and bonus is adjusted. Load is not taken in to consideration. For SIP returns, monthly investment of equal amounts invested on the 1st day of every month has been considered.

For scheme performance refer pages 54 - 68.

*B: Benchmark, AB: Additional Benchmark; For Scheme Risk-O-Meter and Scheme Benchmark Risk-O-Meter please refer page number 69 of Factsheet.

Source: MFI Explorer

Top 10 Holdings Equity


Issuer Name	% to NAV
Sun Pharmaceutical Industries Ltd.	11.29
Divi Laboratories Ltd.	8.86
Dr. Reddys Laboratories Ltd.	7.98
Cipla Ltd.	7.77
Alkem Laboratories Ltd.	7.08
Apollo Hospitals Enterprise Ltd.	6.36
Ipca Labs	5.65
Narayana Hrudayalaya Ltd.	4.36
Fortis Healthcare Ltd.	3.79
J.b.chemicals & Pharmaceuticals Ltd.	2.88
Total	66.02

Market Capitalisation wise Exposure

Large Cap	49.36%
Mid Cap	30.03%
Small Cap	20.61%

Market Capitalisation is as per list provided by AMFI.

Sector Allocation



NAV Movement

